Skip to main content
. 2015 Oct 20;5:15336. doi: 10.1038/srep15336

Figure 4. VC1-8 also enhances the elimination of human RasV12-transformed mammary epithelial cells.

Figure 4

(a) Immunofluorescence images of MDCK-pTR GFP-cSrcY527F cells that are surrounded by MDCK cells in the absence (left) or presence (right) of 2 μM VC1-8. Cells are stained with Hoechst 33342 (blue) and Alexa-Fluor-568-conjuated phalloidin (red). Scale bars: 20 μm. (b) Dose-dependent effect of VC1-8 (16 h) on MDCK-pTR GFP-cSrcY527F cells mixed with MDCK cells (white bar) or cultured alone (gray bar). Data are mean ± SD from three independent experiments. Values are expressed as a ratio relative to DMSO treatment. (c) Fluorescence images of MCF10A-pTR GFP-RasV12 cells that are surrounded by MCF10A cells (top) or cultured alone (bottom) in the absence (left) or presence (right) of 2 μM VC1-8. Scale bar: 50 μm. (d) Dose-dependent effect of VC1-8 (24 h) on MCF10A-pTR GFP-RasV12 cells mixed with MCF10A cells (white bar) or cultured alone (gray bar). Data are mean ± SD from three independent experiments. Values are expressed as a ratio relative to DMSO treatment. *P < 0.05, **P < 0.01, ***P < 0.001.